Current Opinion in Biotechnology (COBIOT) publishes authoritative, comprehensive, and systematic reviews. COBIOT helps specialists keep up to date with a clear and readable synthesis on current advances biotechnology. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.

Current Opinion in Biotechnology is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Biotechnology (CRBIOT). CO+RE journals leverage the Current Opinion legacy of editorial excellence, high-impact, and global reach to ensure they are a widely read resource that is integral to scientists workflow.

Current Opinion in Biotechnology is divided into themed sections, each of which is reviewed once a year. Themes include analytical biotechnology; plant biotechnology; food biotechnology; energy biotechnology; environmental biotechnology; systems biology; nanobiotechnology; tissue, cell and pathway engineering; chemical biotechnology; and pharmaceutical biotechnology.

The journal builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.

• Expertise Expert authors, who are leaders in their field, are invited to write short review articles in which they present recent developments in their subject and provide short annotations to the papers that they think are most relevant.
• Comprehensiveness There are 27 high-impact Current Opinion review journals in a range of subjects from food science to green and sustainable chemistry.
• Impact In addition to a vast readership, Current Opinion titles enjoy high citations, Impact Factors, and CiteScores.